Nervgen Pharma Corp (NGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2005 | 06-2005 | 03-2005 | 12-2004 | 09-2004 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -26,810 | -17,970 | -8,250 | -38,900 | -27,700 |
| Depreciation Amortization | 4,190 | 2,900 | 1,480 | 4,370 | 2,670 |
| Other Working Capital | -3,960 | -2,260 | -2,990 | -2,280 | -2,300 |
| Other Operating Activity | 60 | -200 | -220 | 7,320 | 5,760 |
| Operating Cash Flow | $-26,520 | $-17,530 | $-9,980 | $-29,490 | $-21,570 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,270 | -920 | -430 | -800 | -390 |
| Net Acquisitions | -1,680 | -1,680 | -1,680 | 3,500 | -2,660 |
| Other Investing Activity | 22,190 | 23,430 | 9,320 | -16,490 | -26,860 |
| Investing Cash Flow | $19,240 | $20,830 | $7,210 | $-13,790 | $-29,910 |
| Cash Flows From Financing Activities | |||||
| Other Financing Activity | 19,550 | 130 | 90 | 49,970 | 48,990 |
| Financing Cash Flow | $19,550 | $130 | $90 | $49,970 | $48,990 |
| Exchange Rate Effect | 20 | 20 | 20 | 130 | 10 |
| Beginning Cash Position | 15,370 | 15,370 | 15,370 | 8,550 | 8,550 |
| End Cash Position | 27,670 | 18,820 | 12,710 | 15,370 | 6,060 |
| Net Cash Flow | $12,290 | $3,450 | $-2,650 | $6,820 | $-2,480 |
| Free Cash Flow | |||||
| Operating Cash Flow | -26,520 | -17,530 | -9,980 | -29,490 | -21,570 |
| Free Cash Flow | -26,520 | -17,530 | -9,980 | -29,490 | -21,570 |